Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S. ... Khaki, A. R. (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 20. (5), e440-e452. doi: 10.1016/j.clgc.2022.06.001
Makrakis, Dimitrios, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer, vol. 20, no. 5, 2022, pp. e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001
Makrakis, Dimitrios, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril Ajuria, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer 20, no. 5 (2022): e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001
Makrakis, D., et al. (2022) 'Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma', Clinical Genitourinary Cancer, 20(5), pp. e440-e452. doi: 10.1016/j.clgc.2022.06.001
Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, and sur.. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer [Internet]. 2022 October [cited 2024 October 26];20(5):e440-e452. doi: 10.1016/j.clgc.2022.06.001
D. Makrakis, et al., "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma", Clinical Genitourinary Cancer, vol. 20, no. 5, pp. e440-e452, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:127:400491. [Accessed: 26 October 2024]